European Neuropsychopharmacology最新文献

{"title":"Targeting affective cognition during pregnancy to prevent postpartum depression: a randomized controlled trial with parity-specific effects.","authors":"Anne Bjertrup, Karoline He Rasmussen, Sille Tørring, Kamilla W Miskowiak","doi":"10.1016/j.euroneuro.2026.113885","DOIUrl":"https://doi.org/10.1016/j.euroneuro.2026.113885","url":null,"abstract":"<p><p>Postpartum depression (PPD) affects approximately 17% of women globally and is predicted by prior mental illness and socioeconomic disadvantage. Emerging evidence suggests that negative bias in the cognitive processing of infant cues and heightened reactivity to infant distress during pregnancy contribute to PPD risk and may thus represent a treatment target. This randomized controlled trial examined whether prenatal affective cognitive training (PACT) reduces PPD risk by modulating negative biases in pregnant women at heightened risk. Of 280 women assessed, 147 at heightened risk were randomized to PACT or care as usual (CAU). PACT comprised five individualized 90-minute sessions over five weeks, combining computerized and virtual-reality tasks targeting negative cognitive bias, attentional bias, emotion regulation, and working memory in response to infant stimuli. Affective cognition was assessed at baseline and post-intervention; mood was rated at baseline, post-intervention, and weekly for six weeks after birth. Diagnostic interviews (Present State Examination) were conducted six months postpartum. The primary outcome was PPD incidence within six months postpartum; secondary outcomes included depressive symptoms over the first six weeks and changes in affective cognition. Follow-up data were available for 121 (83%) participants (PACT n = 54; CAU n = 67). PACT did not significantly reduce PPD overall (p = 0.18) or depressive symptoms (p = 0.31) but increased positive interpretation of infant emotions (p = 0.003). Exploratory analyses indicated lower PPD incidence among multiparous participants receiving PACT than CAU (5% vs. 35%; OR=0.10, 95% CI [0.01-0.92], p = 0.04) and additional parity-specific changes in affective cognition. These exploratory findings require replication in larger trials. TRIAL REGISTRATION: The trial was registered at ClinicalTrials.gov with Trial number NCT06046456 on 21 September 2023 https://clinicaltrials.gov/study/NCT06046456.</p>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"114 ","pages":"113885"},"PeriodicalIF":8.1,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personality, not cognition, distinguishes chronic ayahuasca and cannabis users from non-users","authors":"José Carlos Bouso ,&nbsp;Oscar Andión ,&nbsp;Sabela Fondevila Estévez ,&nbsp;Débora González ,&nbsp;Miguel Ángel Alcázar-Córcoles ,&nbsp;Maja Kohek ,&nbsp;Rafael Guimaraes dos Santos ,&nbsp;Jaime Hallak ,&nbsp;Jordi Riba","doi":"10.1016/j.euroneuro.2026.112782","DOIUrl":"10.1016/j.euroneuro.2026.112782","url":null,"abstract":"<div><div>The increasing interest in the therapeutic potential of psychedelics and cannabis underscores the need to understand their long-term neuropsychological and personality effects. This cross-sectional study compared regular users of ayahuasca (<em>n</em> = 69), cannabis (<em>n</em> = 56), and non-substance users (<em>n</em> = 94) on a battery of neuropsychological tasks and psychological questionnaires. Participants were matched by age, education, and IQ and abstained from drug use for at least 10–30 days before assessment. No significant group differences were observed in neuropsychological performance. However, multinomial regression analyses revealed that personality traits best distinguished the user groups. Ayahuasca users exhibited significantly higher self-transcendence and lower harm avoidance and persistence, while cannabis users were associated with higher novelty seeking and impulsive nonconformity, as well as lower introvertive anhedonia. These results persisted after controlling for demographics and psychiatric history. Contrary to previous findings associating cannabis with neurocognitive impairments and psychopathology, no significant deficits were found in the abstinent cannabis users. Similarly, ayahuasca users, despite a higher lifetime prevalence of mood and anxiety disorders, showed no current psychopathological symptoms. Our findings suggest that chronic use of ayahuasca or cannabis is not associated with detectable lasting neuropsychological impairments in the executive and working memory tasks assessed in this study, and that personality characteristics—rather than cognition or psychopathology—most clearly distinguish chronic users from non-users. However, these results are based on a cross-sectional, self-selected, non–treatment-seeking sample and may therefore not be representative of all ayahuasca and cannabis users. These insights may inform future clinical applications and safety evaluations of these substances.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"106 ","pages":"Article 112782"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146170908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Major depression and atherosclerotic disease: Linking shared genetics to pathways in blood, brain, heart, and atherosclerotic plaques","authors":"Emma Pruin ,&nbsp;Meike Bartels ,&nbsp;Ernest Diez Benavente ,&nbsp;Noortje A.M. van den Dungen ,&nbsp;Joost K.R. Hoekstra ,&nbsp;Dominique D.P. de Kleijn ,&nbsp;Lennart P.L. Landsmeer ,&nbsp;Michal Mokry ,&nbsp;Gerard Pasterkamp ,&nbsp;Brenda W.J.H. Penninx ,&nbsp;Wouter J. Peyrot ,&nbsp;Hester M. den Ruijter ,&nbsp;Sander W. van der Laan ,&nbsp;Yuri Milaneschi","doi":"10.1016/j.euroneuro.2026.112780","DOIUrl":"10.1016/j.euroneuro.2026.112780","url":null,"abstract":"<div><div>The increased risk of atherosclerotic diseases (stroke, coronary artery disease [CAD]) observed in depression may stem from shared pathophysiology. We examined whether: 1) major depression (MD) and atherosclerotic traits share genetic risk, and 2) altered gene expression in various tissues linked to shared genetics has a potential causal role in depression etiology. Data from the largest genome-wide association studies of MD (<em>N</em> = 3,887,532) and 8 atherosclerotic traits (<em>N</em> = 26,909–1,308,460) were used in Two-Sample Mendelian randomization and colocalization to detect cross-trait causal associations and genomic loci containing shared causal variants. In shared loci, summary data-based Mendelian randomization estimated the effects of gene expression on MD etiology using expression quantitative trait loci datasets from whole blood, brain and heart tissues and atherosclerotic plaques from the Athero-Express Biobank Study. MD genetic liability increased risk of any stroke (OR=1.15, <em>p</em> = 9.47 × 10^–8), ischemic stroke (OR=1.16, <em>p</em> = 1.52 × 10^–7), small vessel disease (OR=1.34, <em>p</em> = 4.76 × 10^–5) and CAD (OR=1.2, 95 %CIs=1.13–1.26, <em>p</em> = 3.76 × 10^–22). Eight genomic regions harbored potentially shared causal variants, including one on chromosome 7 linking MD with any stroke, ischemic stroke and CAD. Altered expression of 16 genes in blood, 10 in brain, and 6 in heart was found causal for MD etiology. In atherosclerotic plaques, one gene was linked to MD at nominal significance only. Major depression and atherosclerotic diseases share genetic risk potentially acting in depression pathophysiology through expression of genes in blood, brain and heart tissues. Involvement of atherosclerotic plaques in depression etiology was not supported. Identified pathways could guide the development of new treatments to prevent depression-heightened atherosclerotic risk.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"106 ","pages":"Article 112780"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146075806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Esketamine in bipolar depression: Unreproducible data","authors":"Liang-Chun Wang ,&nbsp;Joshua Wang","doi":"10.1016/j.euroneuro.2026.112765","DOIUrl":"10.1016/j.euroneuro.2026.112765","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"106 ","pages":"Article 112765"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146026047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “All-cause and cause-specific mortality in people with mental disorders: a population-based study on risk evaluation, effect modifiers and excess life-years lost in Hong Kong”","authors":"Hailun Xia,&nbsp;Yuanyi Yang","doi":"10.1016/j.euroneuro.2026.112781","DOIUrl":"10.1016/j.euroneuro.2026.112781","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"106 ","pages":"Article 112781"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146075844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies for enhancing methodological rigor and clinical relevance of eating disorders-schizophrenia spectrum disorders risk association studies","authors":"Jing-Ying Ma ,&nbsp;FaDan Tang ,&nbsp;Yonghua Zhang ,&nbsp;Jue Hu","doi":"10.1016/j.euroneuro.2026.112785","DOIUrl":"10.1016/j.euroneuro.2026.112785","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"106 ","pages":"Article 112785"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146170906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of treatment success in patients with substance use disorder (SUD) and co-morbid attention deficit/hyperactivity disorder (ADHD): Results from the International Naturalistic Cohort Study of ADHD and SUD (INCAS)","authors":"Christoffer Brynte ,&nbsp;Arnt Schellekens ,&nbsp;Maija Konstenius ,&nbsp;Alex Hendrikus Abraham Begeman ,&nbsp;Cleo Lina Crunelle ,&nbsp;Zsolt Demetrovics ,&nbsp;Geert Dom ,&nbsp;Romain Icick ,&nbsp;Brian Johnson ,&nbsp;Máté Kapitány-Fövény ,&nbsp;Frances R. Levin ,&nbsp;Mathias Luderer ,&nbsp;Frieda Matthys ,&nbsp;Franz Moggi ,&nbsp;Raul Felipe Palma-Álvarez ,&nbsp;J․Antoni Ramos-Quiroga ,&nbsp;Andreas Reif ,&nbsp;Michiel W. van Kernebeek ,&nbsp;María C. Vélez-Pastrana ,&nbsp;Wim van den Brink ,&nbsp;Johan Franck","doi":"10.1016/j.euroneuro.2026.112783","DOIUrl":"10.1016/j.euroneuro.2026.112783","url":null,"abstract":"<div><div>Comorbid attention deficit/hyperactivity disorder (ADHD) and substance use disorder (SUD) is associated with poor treatment outcomes. This international multi-center observational prospective cohort study aimed to gain knowledge about predictors of treatment outcomes in adult SUD+ADHD patients. Data was collected from June 2017 to May 2021 at baseline, four weeks, three months, and nine months at twelve treatment services in nine countries. Main outcomes were: Treatment retention, ≥30% reduction from baseline to follow-up according to the adult ADHD self-report scale (ASRS-18), and self-reported substance use at three-month follow-up.</div><div>A total of 137 adult females (24 %) and 441 adult males (76 %) were enrolled. Receiving stimulant treatment for ADHD was significantly associated with better treatment retention (OR: 2·4, 95% CI: 1·4–4·2), ≥30% reduction in ASRS total score (OR: 2·6, 95% CI: 1·2–6·1), and fewer heavy drinking days (IRR: 0·24, 95% CI: 0·13–0·42) at three months. Psychosocial treatment for ADHD was independently and significantly associated with fewer heavy drinking days at three months (IRR: 0·27, 95% CI: 0·14–0·51).</div><div>In summary, treatment of ADHD in SUD+ADHD patients was related to improvements in ADHD-symptoms, treatment retention and fewer heavy drinking days at follow-up. These findings highlight the importance of ADHD treatment provision in this population. Future RCTs are warranted to confirm these results and should assess combinations of ADHD treatments and SUD treatments using different doses of stimulants.</div><div>Trial Registration: ISRCTN (<span><span>https://doi.org/10.1186/ISRCTN15998989</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"106 ","pages":"Article 112783"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of adjunctive treatment with the fatty acid amide hydrolase inhibitor JNJ-42165279 in participants with major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomised study","authors":"Mark E. Schmidt ,&nbsp;Cynthia Gargano ,&nbsp;Xianhuang Zhou ,&nbsp;James A. Palmer ,&nbsp;Ziad S. Saad ,&nbsp;Eduard Vieta ,&nbsp;Wayne C. Drevets ,&nbsp;Kim Stuyckens ,&nbsp;Gahan Pandina","doi":"10.1016/j.euroneuro.2026.112771","DOIUrl":"10.1016/j.euroneuro.2026.112771","url":null,"abstract":"<div><div>JNJ-42165279 is a potent, selective inhibitor of fatty acid amide hydrolase (FAAH), the enzyme responsible for degradation of the endocannabinoid N-arachidonoylethanolamide (anandamide), which plays a role in regulation of fear and anxiety responses. This double-blind, randomised, placebo-controlled, phase 2a study assessed the efficacy, safety and pharmacodynamics of adjunctive treatment with JNJ-42165279 in participants with major depressive disorder (MDD) with anxious distress and inadequate response to selective serotonin reuptake inhibitors (SSRI) or serotonergic/noradrenergic reuptake inhibitors (SNRI). Eligible participants (18-64 years; <em>N</em> = 153) were randomised (1:1) to receive JNJ-42165279 (25 mg) or placebo orally once daily and were maintained on their current SSRI/SNRI treatment. The primary endpoint was the change from baseline at week 6 in the 17-item Hamilton Depression Rating Scale (HDRS₁₇). The study results did not show a significant treatment effect of adjunctive JNJ-42165279 on the primary endpoint versus placebo (least square mean difference [standard error]: ˗0.2 [1.04]; one-sided p=0.416) in the enriched intent-to-treat population. Findings for the key secondary efficacy endpoints also did not demonstrate an additional benefit of adjunctive JNJ-42165279 treatment over placebo. Treatment with JNJ-42165279 produced substantial increases in the mean concentrations of fatty acid amides in plasma, and the plasma JNJ-42165279 and anandamide levels were strongly correlated. The safety results were consistent with the known safety profile of JNJ-42165279. Overall, adjunctive treatment with JNJ-42165279 at the dose tested did not provide significant benefit in reducing depression/anxiety symptoms versus placebo but showed no new safety signals in participants with MDD and anxious distress.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"106 ","pages":"Article 112771"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146075843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the letter regarding \"risk of manic switch and suicidal outcomes in bipolar depression treated with esketamine\"","authors":"Ting-Hui Liu ,&nbsp;Chih-Cheng Lai","doi":"10.1016/j.euroneuro.2026.112766","DOIUrl":"10.1016/j.euroneuro.2026.112766","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"106 ","pages":"Article 112766"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146006813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traumatic loss, bereavement, and prolonged grief disorder in times of war: insights from Ukraine","authors":"Iryna Frankova ,&nbsp;Iryna Leshchuk","doi":"10.1016/j.euroneuro.2026.112768","DOIUrl":"10.1016/j.euroneuro.2026.112768","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"106 ","pages":"Article 112768"},"PeriodicalIF":6.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146026046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}